Kite Pharma gets Yescarta approval in Japan for large B-cell lymphoma
Kite Pharma, a subsidiary of Gilead Sciences, and Daiichi Sankyo have received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for their Yescarta (axicabtagene ciloleucel) for initial treatment of relapsed/refractory large B-cell lymphoma (LBCL). Yescarta, a chimeric antigen receptor (CAR) T-cell therapy, is used only in patients who have not received a […]